Drug
131i Omburtamab
131i Omburtamab: highest development phase Phase 2/3, developed by Y-mAbs Therapeutics. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2/3
- Developer
- Y-mAbs Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| 131I-omburtamab NCT03275402 | Phase 2/3 | Neuroblastoma |
| 131I-Omburtamab NCT05063357 | Phase 1 | DIPG |
Latest
No recent events.
Follow 131i Omburtamab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.